[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335590-105":59,"doc-detail-335590-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exploring-pdk3-inhibition-in-lung-cancer-through-drug-repurposing-for-potential-therapeutic-interventions","Exploring PDK3 inhibition in lung cancer through drug repurposing for potential therapeutic interventions","","The study investigates pyruvate dehydrogenase kinase-3 (PDK3) as a cancer-relevant regulator that suppresses the pyruvate dehydrogenase complex, redirecting energy metabolism toward glycolysis required for lung cancer survival. A computer-based drug design workflow screened an FDA-approved library of 3839 compounds to identify candidates with strong binding affinity and specific interactions. Bagrosin and dehydrocholic acid were selected based on docking results and binding affinities around −10.6 and −10.5 kcal/mol, respectively. Molecular dynamics simulations over 100 ns indicated stable PDK3-ligand complexes via RMSD, RMSF, Rg, and SASA, with PCA and FEL supporting global energy minima for both complexes. The work highlights these FDA-approved drugs as potential resources for developing therapeutic interventions, while emphasizing the need for further clinical validation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploring-pdk3-inhibition-in-lung-cancer-through-drug-repurposing-for-potential-therapeutic-interventions/335590/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploring-pdk3-inhibition-in-lung-cancer-through-drug-repurposing-for-potential-therapeutic-interventions/335590.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is PDK3 considered relevant to lung cancer metabolism?","Question",{"text":112,"@type":113},"PDK3 regulates cancer metabolism by inhibiting the pyruvate dehydrogenase complex, shifting energy production toward glycolysis, which supports cancer cell growth and survival.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were potential PDK3 inhibitors identified in the study?",{"text":117,"@type":113},"The research used a computer-based drug design approach with virtual screening of an FDA-approved library of 3839 compounds, followed by selection based on binding affinity and interaction quality.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence from molecular dynamics supports the selected drug candidates?",{"text":121,"@type":113},"100 ns MD simulations indicated stable PDK3-ligand complexes, reflected by RMSD, RMSF, Rg, and SASA metrics, and PCA/FEL analysis suggested global energy minima for the complexes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335590,1790033256,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nExploring PDK3 inhibition in lung cancer through drug repurposing for potential therapeutic interventions  \nZeba Firdos Khan1, Aanchal Rathi2, Afreen Khan3, Farah Anjum4, Arunabh Chaudhury3, Aaliya Taiyab3, Anas Shamsi5􀀍 & Md. Imtaiyaz Hassan3􀀍  \nThe pyruvate dehydrogenase kinase-3 (PDK3) plays an important role in the regulation of a variety of cancers, including lung, by inhibiting the pyruvate dehydrogenase complex (PDC), shifting energy production towards glycolysis necessary for cancer metabolism. In this study, we aimed to identify potential PDK3 inhibitors using a computer-based drug design approach. Virtual screening of the FDA-approved library of 3839 compounds was carried out, from which Bagrosin and Dehydrocholicacid appeared best due to their strong binding affinity, specific interactions, and potential biological characteristics, and thus were selected for further investigations. Both compounds show strong interactions with functionally important residues of the PDK3 with a binding affinity of − 10.6 and − 10.5 kcal/mol for Bagrosin and Dehydrocholic acid, respectively. MD simulation studies for 100 ns suggest the formation of stable complexes, which is evident from RMSD, RMSF, Rg, and SASA parameters. The PCA and FEL analysis suggested admirable global energy minima for the bagrosinPDK3 and dehydrocholic acid-PDK3 complexes. Finally, we identified FDA-approved drugs, Bagrosinand Dehydrocholic acid, that offer valuable resources and potential therapeutic molecules for targeting lung cancer. Further clinical investigations are required to validate the clinical utility of selected molecules.  \nKeywords Pyruvate dehydrogenase kinase-3, FDA-approved drugs, Lung cancer, Virtual screening, MD simulation, Drug discovery  \nLung cancer is one of the most common types in the world1. In the UK alone, there were 46,403 new cases of lung cancer in 2014, which is quite surprising. Even though it’s the third most common cancer overall, it is the top cause of cancer-related deaths, contributing to 18% of deaths globally. It is estimated to account for 127,070 deaths in 20232,3. Unfortunately, in 93 countries, lung cancer is the leading cause of cancer death among men because it has a high mortality rate4. In certain countries, like China, Indonesia, and some African nations, lung cancer rates are still increasing5. India ranks third in the world for both tobacco production and consumption, with approximately 28.6% of its population using tobacco products. Lung cancer accounts for 5.9% of all cancer cases and 8.1% of cancer-related deaths in the country6. Cigarette smoking, responsible for 80% of lung cancer cases and deaths, significantly raises the risk, while additional factors such as secondhand smoke, radon, asbestos, and air pollution7,8. Hence, there is an immediate need to develop therapeutic advances that can overcome the drawbacks of current treatments9.  \nEnergy is necessary for life, and animals obtain their energy through the process of oxidative phosphorylation (OXPHOS) in their mitochondria10. However, most cancer cells have a different way of getting energy, as they can produce lactate from glucose even in the presence of adequate oxygen11, 12, a process known as the Warburg effect or Aerobic glycolysis. This change helps cancer cells promote their growth and avoid dying, serving as a  \n1Department of Biosciences, Faculty of Life Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India.  \n2Department of Biotechnology, Faculty of Life Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India.  \n3Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India.  \n4Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, PO Box 11099, 21944 Taif, Saudi Arabia. 5Center of Medical and Bio-Allied Health Sciences Research (CMBHSR)","cbCaib6yCqa6B6On","https://ap.wps.com/l/cbCaib6yCqa6B6On","pdf",3900464,14,"English","# Exploring PDK3 inhibition in lung cancer through drug repurposing\n## Virtual screening and compound selection\n## Molecular docking and binding affinity assessment\n## Molecular dynamics simulations and stability evaluation\n## Energy landscape analysis (PCA and FEL)\n## Implications for potential therapeutic interventions","[{\"question\":\"Why is PDK3 considered relevant to lung cancer metabolism?\",\"answer\":\"PDK3 regulates cancer metabolism by inhibiting the pyruvate dehydrogenase complex, shifting energy production toward glycolysis, which supports cancer cell growth and survival.\"},{\"question\":\"How were potential PDK3 inhibitors identified in the study?\",\"answer\":\"The research used a computer-based drug design approach with virtual screening of an FDA-approved library of 3839 compounds, followed by selection based on binding affinity and interaction quality.\"},{\"question\":\"What evidence from molecular dynamics supports the selected drug candidates?\",\"answer\":\"100 ns MD simulations indicated stable PDK3-ligand complexes, reflected by RMSD, RMSF, Rg, and SASA metrics, and PCA/FEL analysis suggested global energy minima for the complexes.\"}]","Exploring PDK3 inhibition in lung cancer through drug repurposing for potential therapeutic interventions | PDF",1790011544,35]